Wednesday, September 13, 2017 5:39:03 PM
Just a reminder that we are over 40 months past the time **median enrollment was met. (aka: or about **165 patients.).
We are about 25.5 months since last surgery/screening.
We are at about 22.5 months since last enrollment.
The trial is pragmatically about 5.5 years old and literally almost ten years old.
There are likely approximately 95 to 99 (29% +) patients still alive, imho.
There are likely still over 70 patients that have not progressed, imho. If all estimated 71+ not progressed are from the treatment group, that would be about one-third or more after all this time.
This trial excluded long lived psPD from the main trial. This likely means they excluded many long lived methylated MGMT. IMHO.
IMHO, the trial has a long tail for:
1. ITT OS -- probable treatment arm.
2. Treatment arm for PFS.
PFS is mature, imho.
This is all in my humble opinion
We are about 25.5 months since last surgery/screening.
We are at about 22.5 months since last enrollment.
The trial is pragmatically about 5.5 years old and literally almost ten years old.
There are likely approximately 95 to 99 (29% +) patients still alive, imho.
There are likely still over 70 patients that have not progressed, imho. If all estimated 71+ not progressed are from the treatment group, that would be about one-third or more after all this time.
This trial excluded long lived psPD from the main trial. This likely means they excluded many long lived methylated MGMT. IMHO.
IMHO, the trial has a long tail for:
1. ITT OS -- probable treatment arm.
2. Treatment arm for PFS.
PFS is mature, imho.
This is all in my humble opinion
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
